Repositorio UFRO · Omeka S

Enzyme Engineering Strategies for the Bioenhancement of <sc>l</sc>-Asparaginase Used as a Biopharmaceutical

Primer Autor	Zamorano, Mauricio
Co-autores	Miranda, Javiera Lefin, Nicolas Beltran, Jorge F. Belen, Lisandra Herrera Tsipa, Argyro Farias, Jorge G.
Título	Enzyme Engineering Strategies for the Bioenhancement of <sc>l</sc>-Asparaginase Used as a Biopharmaceutical
Editorial	ADIS INT LTD
Revista	BIODRUGS
Lenguaje	en
Resumen	Over the past few years, there has been a surge in the industrial production of recombinant enzymes from microorganisms due to their catalytic characteristics being highly efficient, selective, and biocompatible. l-asparaginase (l-ASNase) is an enzyme belonging to the class of amidohydrolases that catalyzes the hydrolysis of l-asparagine into l-aspartic acid and ammonia. It has been widely investigated as a biologic agent for its antineoplastic properties in treating acute lymphoblastic leukemia. The demand for l-ASNase is mainly met by the production of recombinant type II l-ASNase from Escherichia coli and Erwinia chrysanthemi. However, the presence of immunogenic proteins in l-ASNase sourced from prokaryotes has been known to result in adverse reactions in patients undergoing treatment. As a result, efforts are being made to explore strategies that can help mitigate the immunogenicity of the drug. This review gives an overview of recent biotechnological breakthroughs in enzyme engineering techniques and technologies used to improve anti-leukemic l-ASNase, taking into account the pharmacological importance of l-ASNase.
Fecha Publicación	2023
Tipo de Recurso	artículo de revisión
doi	10.1007/s40259-023-00622-5
Formato Recurso	PDF
Palabras Claves	Antineoplastic Agents / therapeutic use Asparaginase / therapeutic use Biological Factors Biological Products / therapeutic use Escherichia coli / metabolism Humans Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Protein Engineering / methods
Ubicación del archivo	http://dx.doi.org/10.1007/s40259-023-00622-5
Categoría OCDE	Oncología Inmunología Farmacología y Farmacia
Materias	Agentes Antineoplásicos/uso terapéutico Asparaginasa/uso terapéutico Factores Biológicos Productos Biológicos/uso terapéutico Escherichia coli/metabolismo Humanos Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia farmacológica Ingeniería de proteínas / métodos
Página de inicio (Recomendado-único)	793.0
Página final (Recomendado-único)	811
Identificador del recurso (Mandatado-único)	artículo de revisión
Versión del recurso (Recomendado-único)	versión publicada
Derechos de acceso	metadata
Access Rights	metadata
Id de Web of Science	WOS:001067824200001
ISSN	1173-8804
Categoría WOS	Oncología Inmunología Farmacología y Farmacia
Referencia del Financiador (Mandatado si es aplicable-repetible)	FAPESP UFRO 2020/06982-3